Description
Mibolerone 0,5 mg Astera Labs — Manufactured to exacting pharmaceutical standards, designed for targeted physiological enhancement. Manufactured under strict quality standards. This formulation is dosed at 0,5 mg per unit.
Key Benefits
- MENT — 7α-methyl 19-nortestosterone; designed as male contraceptive
- 10× anabolic potency vs testosterone in animal models
- Does not convert to DHT or dihydrotestosterone-analogue
- Aromatises (to 7α-methylestradiol) — AI required
- Investigational / research-grade use only
- Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 50–100 mg/week SubQ or IM split EOD. Short ester (acetate) typical. Cycles 8–10 weeks. Higher doses explored in clinical trials for contraception (more potent suppression wanted there).
How It Works
7α-methyl 19-nortestosterone (MENT). Modified nandrolone derivative with methyl substitution at C7α blocking 5α-reductase action and stabilising oral/injectable activity. Powerful AR agonist; aromatises via CYP19 to 7α-methylestradiol.
Pharmacokinetics
Acetate ester: plasma half-life approximately 30 hours. EOD or M/W/F pinning. Enanthate variants exist with longer kinetics.
Potential Side Effects
HPTA suppression severe — explicit design goal for contraceptive research. Aromatisation requires AI. Long-term human safety data limited. Investigational-status risk profile.
Cycle & Stacking Guide
8–10 week cycles at 50–100 mg/week EOD. Full PCT required. AI (anastrozole 0.25–0.5 mg EOD) mandatory. Not a first-cycle compound.
Manufacturer Notes
Astera Labs produces a broad catalogue from research peptides to AAS oils. Lyophilised peptide vials ship with stability documentation.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.